Steroid Dosing, Surgery Outcomes for COVID-19 Patients, and More: Highlights from 2021 Research
July 1, 2022
Drs. Frank and Grant did an outstanding job with their in-person In the Literature at SHM Converge. Whether to use a standard or a personalized dose of corticosteroids in hospitalized patients...
Administration of probiotic did not reduce ventilator-associated pneumonia in critically ill patients requiring mechanical ventilation
January 7, 2022
Dr. Berry Clinical question: Does administration of probiotic L rhamnosus GG to critically ill patients requiring mechanical ventilation decrease ventilator-associated pneumonia (VAP)...
Ceftolozane-tazobactam found effective in critically ill patients with Pseudomonas aeruginosa infections
January 29, 2021
The primary outcome of the study was to assess the efficacy and toxicity of C/T therapy.
Potentially practice-changing bacterial therapy trials analyzed
October 29, 2020
Intravenous fosfomycin could improve treatment of complicated UTIs, but adjunctive inhaled amikacin did not improve pneumonia outcomes in ventilated patients.
FDA approves new antibiotic for HABP/VABP treatment
June 5, 2020
Recarbrio was previously approved by the FDA to treat patients with complicated urinary tract infections and complicated intra-abdominal infections.
FLU/SAL inhalers for COPD carry greater pneumonia risk
June 4, 2020
Pneumonia risks from different types of inhaled corticosteroids have not been well understood.
CDC: Five confirmed 2019-nCoV cases in the U.S.
January 27, 2020
At this time in the United States, the virus is not spreading in the community.
Guideline: Diagnosis and treatment of adults with community-acquired pneumonia
November 22, 2019
The practice guideline was jointly written by an ad hoc committee of the American Thoracic Society and Infectious Diseases Society of America.
In-hospital flu shot reduced readmissions in pneumonia patients
October 22, 2019
NEW ORLEANS – In-hospital influenza vaccination linked to lower readmission rates in database analysis.
Lefamulin found noninferior to moxifloxacin for bacterial pneumonia
October 1, 2019
Oral lefamulin, the first pleuromutilin antibiotic approved for intravenous and oral administration, was noninferior to oral moxifloxacin for inducing an early clinical response in patients with bacterial pneumonia, acording to data from a global multicenter study of 738 individuals.